238(top 1%)
PR articles
73.6K(top 0.1%)
PR citations
106(top 0.1%)
PR h-index
116(top 0.1%)
h-index
268
documents
105.0K
doc citations
4.2K
citing journals
100
times ranked

Publications

241 peer-reviewed articles • 82,312 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Analysis of Shared Variants between Cancer Biospecimens
Clinical Cancer Research, 2025, 31, 376-386
6.82Citations (PDF)
2Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma
Cancer Discovery, 2025, 15, 1180-1202
25.139Citations (PDF)
3Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Cancer Discovery, 2024, 14, 49-65
25.1348Citations (PDF)
4Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry
Cancer Research Communications, 2024, 4, 475-486
2.84Citations (PDF)
5Deep-Learning Model for Tumor-Type Prediction Using Targeted Clinical Genomic Sequencing Data
Cancer Discovery, 2024, 14, 1064-1081
25.128Citations (PDF)
6Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series
Clinical Cancer Research, 2024, 30, 2272-2285
6.827Citations (PDF)
7Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer
Clinical Cancer Research, 2024, 30, 2672-2683
6.89Citations (PDF)
8Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
Cancer Discovery, 2024, 14, 711-726
25.1159Citations (PDF)
9A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier
Clinical Cancer Research, 2024, 30, 3499-3511
6.89Citations (PDF)
10Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
Clinical Cancer Research, 2024, 30, 3894-3903
6.852Citations (PDF)
11Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Clinical Cancer Research, 2024, 30, 3881-3893
6.813Citations (PDF)
12A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Clinical Cancer Research, 2024, 30, 4005-4015
6.824Citations (PDF)
13DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Nature Medicine, 2024, 30, 2499-2507
33.034Citations (PDF)
14Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors
Oncogene, 2024, 43, 2806-2819
6.53Citations (PDF)
15Obesity-dependent selection of driver mutations in cancer
Nature Genetics, 2024, 56, 2318-2321
25.217Citations (PDF)
16Shareable artificial intelligence to extract cancer outcomes from electronic health records for precision oncology research
Nature Communications, 2024, 15,
13.719Citations (PDF)
17Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
Nature Communications, 2023, 14,
13.751Citations (PDF)
18The Impact of Germline Alterations in Appendiceal Adenocarcinoma
Clinical Cancer Research, 2023, 29, 2631-2637
6.88Citations (PDF)
19The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Clinical Cancer Research, 2023, 29, 3418-3428
6.834Citations (PDF)
20Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Clinical Cancer Research, 2023, 29, 3633-3640
6.829Citations (PDF)
21Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis
Nature Communications, 2023, 14,
13.758Citations (PDF)
22Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal
Cancer Research, 2023, 83, 3861-3867
3.8838Citations (PDF)
23Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy
Annals of Surgery, 2022, 276, e474-e482
4.623Citations (PDF)
24Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors
Clinical Cancer Research, 2022, 28, 318-326
6.852Citations (PDF)
25Association of genomic profiles and survival in early onset and screening‐age colorectal cancer patients with liver metastases resected over 15 years
Journal of Surgical Oncology, 2022, 125, 880-888
1.59Citations (PDF)
26Computational methods and translational applications for targeted next‐generation sequencing platforms
Genes Chromosomes and Cancer, 2022, 61, 322-331
3.06Citations (PDF)
27Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Cell, 2022, 185, 563-575.e11
33.6582Citations (PDF)
28Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
European Urology Focus, 2022, 8, 1278-1288
3.526Citations (PDF)
29Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
Molecular Cancer Therapeutics, 2022, 21, 831-843
1.94Citations (PDF)
30Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Nature Communications, 2022, 13,
13.7213Citations (PDF)
31The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Clinical Cancer Research, 2022, 28, 3603-3617
6.851Citations (PDF)
32Proceedings of the fifth international Molecular Pathological Epidemiology (MPE) meeting
Cancer Causes and Control, 2022, 33, 1107-1120
1.71Citations (PDF)
33AACR Project GENIE: 100,000 Cases and Beyond
Cancer Discovery, 2022, 12, 2044-2057
25.198Citations (PDF)
34Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Nature Medicine, 2022, 28, 1646-1655
33.0134Citations (PDF)
35Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma
Targeted Oncology, 2022, 17, 517-527
3.226Citations (PDF)
36A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting c-fos
Science Translational Medicine, 2022, 14,
12.515Citations (PDF)
37Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
Cancer Discovery, 2022, 12, 2552-2565
25.176Citations (PDF)
38Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Clinical Cancer Research, 2022, 28, 5359-5367
6.850Citations (PDF)
39Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Nature Medicine, 2022, 28, 2353-2363
33.0148Citations (PDF)
40Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors
Nature Cancer, 2021, 2, 357-365
22.5157Citations (PDF)
41A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
JAMA Surgery, 2021, 156, e205601
8.896Citations (PDF)
42OncoTree: A Cancer Classification System for Precision Oncology
JCO Clinical Cancer Informatics, 2021, , 221-230
2.0131Citations (PDF)
43Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study
Gynecologic Oncology, 2021, 160, 696-703
3.04Citations (PDF)
44Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Clinical Cancer Research, 2021, 27, 3491-3498
6.819Citations (PDF)
45The genomic landscape of carcinomas with mucinous differentiation
Scientific Reports, 2021, 11,
3.418Citations (PDF)
46A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles
Cell Reports Methods, 2021, 1, 100039
3.225Citations (PDF)
47CD38 in Advanced Prostate Cancers
European Urology, 2021, 79, 736-746
2.138Citations (PDF)
48Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
JAMA Network Open, 2021, 4, e2114753
6.625Citations (PDF)
49Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Clinical Cancer Research, 2021, 27, 5595-5606
6.823Citations (PDF)
50Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer
JAMA Network Open, 2021, 4, e2117547
6.636Citations (PDF)
51A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers
Journal of the National Cancer Institute, 2021, 113, 1683-1692
4.6188Citations (PDF)
52Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma
Hepatology, 2021, 74, 1429-1444
10.1152Citations (PDF)
53Patterns of Metastatic Disease in Patients with Cancer Derived from Natural Language Processing of Structured CT Radiology Reports over a 10-year Period
Radiology, 2021, 301, 115-122
8.748Citations (PDF)
54Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Clinical Cancer Research, 2021, 27, 2226-2235
6.846Citations (PDF)
55The context-specific role of germline pathogenicity in tumorigenesis
Nature Genetics, 2021, 53, 1577-1585
25.298Citations (PDF)
56Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights
Nature Communications, 2021, 12,
13.741Citations (PDF)
57Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care
JAMA Oncology, 2020, 6, 84
14.3105Citations (PDF)
58Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma
JAMA Oncology, 2020, 6, 60
14.3211Citations (PDF)
59Specific Mutations in APC, but Not Alterations in DNA Damage Response, Associate With Outcomes of Patients With Metastatic Colorectal Cancer
Gastroenterology, 2020, 159, 1975-1978.e4
0.948Citations (PDF)
60The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
Journal of Thoracic Oncology, 2020, 15, 1844-1856
2.1136Citations (PDF)
61First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Lancet Oncology, The, 2020, 21, 821-831
27.4337Citations (PDF)
62Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer
Clinical Cancer Research, 2020, 26, 3230-3238
6.8178Citations (PDF)
63Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Molecular Oncology, 2020, 14, 1881-1897
4.133Citations (PDF)
64Phase and context shape the function of composite oncogenic mutations
Nature, 2020, 582, 100-103
37.945Citations (PDF)
65Recent Advances in Systems and Network Medicine: Meeting Report from the First International Conference in Systems and Network Medicine
Systems Medicine (New Rochelle, N Y ), 2020, 3, 22-35
0.711Citations (PDF)
66Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Clinical Cancer Research, 2020, 26, 3271-3279
6.8201Citations (PDF)
67A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Nature Genetics, 2020, 52, 448-457
25.2164Citations (PDF)
68Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis
Clinical Colorectal Cancer, 2020, 19, e151-e156
2.616Citations (PDF)
69Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer
Oncologist, 2020, 25, e68-e74
3.410Citations (PDF)
70Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry
Cancer Discovery, 2020, 10, 526-535
25.150Citations (PDF)
71Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer
Clinical Cancer Research, 2020, 26, 1077-1085
6.886Citations (PDF)
72Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics
European Urology, 2020, 78, 671-679
2.1117Citations (PDF)
73Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin
Annals of Surgical Oncology, 2020, 28, 1109-1117
2.36Citations (PDF)
74Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Clinical Cancer Research, 2020, 26, 3239-3247
6.8215Citations (PDF)
75Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers
Clinical Cancer Research, 2019, 25, 1063-1069
6.8320Citations (PDF)
76Cancer-associated mutations in DICER1 RNase IIIa and IIIb domains exert similar effects on miRNA biogenesis
Nature Communications, 2019, 10,
13.776Citations (PDF)
77Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer
Clinical Cancer Research, 2019, 25, 6160-6169
6.887Citations (PDF)
78Tumour lineage shapes BRCA-mediated phenotypes
Nature, 2019, 571, 576-579
37.9382Citations (PDF)
79Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal
Molecular and Cellular Proteomics, 2019, 18, 1893-1898
3.0142Citations (PDF)
80Genomic stratification beyond Ras/B‐Raf in colorectal liver metastasis patients treated with hepatic arterial infusion
Cancer Medicine, 2019, 8, 6538-6548
2.613Citations (PDF)
81Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma
Clinical Cancer Research, 2019, 25, 7475-7484
6.839Citations (PDF)
82Genomic correlates of clinical outcome in advanced prostate cancer
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11428-11436
7.51,302Citations (PDF)
83The expanding landscape of ‘oncohistone’ mutations in human cancers
Nature, 2019, 567, 473-478
37.9374Citations (PDF)
84Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer
Clinical Cancer Research, 2019, 25, 3811-3817
6.817Citations (PDF)
85Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
JAMA Oncology, 2019, 5, 471
14.3611Citations (PDF)
86EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer
Cancer Discovery, 2019, 9, 199-209
25.1146Citations (PDF)
87Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate
Molecular Cancer Research, 2019, 17, 446-456
3.156Citations (PDF)
88Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
Clinical Cancer Research, 2019, 25, 2116-2126
6.8544Citations (PDF)
89FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer
Clinical Colorectal Cancer, 2019, 18, e39-e52
2.628Citations (PDF)
90Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
European Urology, 2019, 75, 231-239
2.1143Citations (PDF)
91Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
Journal of Clinical Investigation, 2019, 129, 4276-4289
10.6199Citations (PDF)
92The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma
Cancer Cell, 2018, 33, 527-541.e8
33.0141Citations (PDF)
93Unifying cancer and normal RNA sequencing data from different sources
Scientific Data, 2018, 5,
5.7216Citations (PDF)
94An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Cell, 2018, 173, 400-416.e11
33.63,383Citations (PDF)
95Comprehensive Characterization of Cancer Driver Genes and Mutations
Cell, 2018, 173, 371-385.e18
33.62,131Citations (PDF)
96Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Cell, 2018, 173, 291-304.e6
33.62,413Citations (PDF)
97A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples
Cell, 2018, 173, 386-399.e12
33.6297Citations (PDF)
98Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Cell, 2018, 173, 305-320.e10
33.6375Citations (PDF)
99Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Cell, 2018, 173, 338-354.e15
33.62,033Citations (PDF)
100Oncogenic Signaling Pathways in The Cancer Genome Atlas
Cell, 2018, 173, 321-337.e10
33.62,971Citations (PDF)
101Pathogenic Germline Variants in 10,389 Adult Cancers
Cell, 2018, 173, 355-370.e14
33.6820Citations (PDF)
102Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types
Cell Reports, 2018, 23, 282-296.e4
6.3432Citations (PDF)
103Driver Fusions and Their Implications in the Development and Treatment of Human Cancers
Cell Reports, 2018, 23, 227-238.e3
6.3583Citations (PDF)
104The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Cell Reports, 2018, 23, 313-326.e5
6.3708Citations (PDF)
105Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images
Cell Reports, 2018, 23, 181-193.e7
6.3960Citations (PDF)
106The Immune Landscape of Cancer
Immunity, 2018, 48, 812-830.e14
22.65,116Citations (PDF)
107Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas
Cell Reports, 2018, 23, 172-180.e3
6.3148Citations (PDF)
108Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Cell Reports, 2018, 23, 239-254.e6
6.31,060Citations (PDF)
109G2S: a web-service for annotating genomic variants on 3D protein structures
Bioinformatics, 2018, 34, 1949-1950
4.711Citations (PDF)
110Accelerating Discovery of Functional Mutant Alleles in Cancer
Cancer Discovery, 2018, 8, 174-183
25.1376Citations (PDF)
111Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Cancer Cell, 2018, 33, 125-136.e3
33.0810Citations (PDF)
112Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Cell Systems, 2018, 6, 282-300.e2
5.8413Citations (PDF)
113lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer
Cancer Cell, 2018, 33, 706-720.e9
33.0457Citations (PDF)
114Genomic and Functional Approaches to Understanding Cancer Aneuploidy
Cancer Cell, 2018, 33, 676-689.e3
33.01,065Citations (PDF)
115Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Cancer Cell, 2018, 33, 721-735.e8
33.0519Citations (PDF)
116A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Cancer Cell, 2018, 33, 690-705.e9
33.0619Citations (PDF)
117The long tail of oncogenic drivers in prostate cancer
Nature Genetics, 2018, 50, 645-651
25.2791Citations (PDF)
118Systematic Functional Annotation of Somatic Mutations in Cancer
Cancer Cell, 2018, 33, 450-462.e10
33.0315Citations (PDF)
119Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis
Clinical Cancer Research, 2018, 24, 1965-1973
6.8120Citations (PDF)
120Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Cancer Discovery, 2018, 8, 49-58
25.1345Citations (PDF)
121American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond—Lessons Learned and Member Institutions’ Perspectives
JCO Clinical Cancer Informatics, 2018, , 1-14
2.040Citations (PDF)
122Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Journal of Clinical Oncology, 2018, 36, 633-641
16.91,314Citations (PDF)
123Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Journal of Clinical Investigation, 2018, 128, 4441-4453
10.6185Citations (PDF)
124Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Cancer Cell, 2018, 34, 893-905.e8
33.0463Citations (PDF)
125A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily
Cell Systems, 2018, 7, 422-437.e7
5.8174Citations (PDF)
126The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Cancer Cell, 2018, 34, 427-438.e6
33.0902Citations (PDF)
127Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Clinical Cancer Research, 2018, 24, 4154-4161
6.8522Citations (PDF)
128KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function
Oncogene, 2018, 37, 4692-4710
6.5131Citations (PDF)
129Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Cancer Cell, 2018, 34, 211-224.e6
33.0890Citations (PDF)
13062 - Shared and Private Genomic Alterations in Colitisassociated Dysplasia and Carcinoma Developing Synchronously within the Same Patient
Gastroenterology, 2018, 154, S-21
0.90Citations (PDF)
131Genome doubling shapes the evolution and prognosis of advanced cancers
Nature Genetics, 2018, 50, 1189-1195
25.2646Citations (PDF)
132Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer
Annals of Surgical Oncology, 2018, 25, 2027-2033
2.327Citations (PDF)
133Integrated Molecular Characterization of Testicular Germ Cell Tumors
Cell Reports, 2018, 23, 3392-3406
6.3437Citations (PDF)
134Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
Gastric Cancer, 2018, 22, 355-362
3.418Citations (PDF)
1353D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets
Genome Medicine, 2017, 9,
9.6208Citations (PDF)
136ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer
Cancer Research, 2017, 77, 1035-1046
3.817Citations (PDF)
137Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Molecular Systems Biology, 2017, 13,
6.781Citations (PDF)
138Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine, 2017, 23, 703-713
33.03,143Citations (PDF)
139Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
Neuro-Oncology, 2017, 19, 1380-1390
1.038Citations (PDF)
140Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Cell, 2017, 169, 1327-1341.e23
33.62,272Citations (PDF)
141Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Cancer Discovery, 2017, 7, 1018-1029
25.1383Citations (PDF)
142ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis
Nature, 2017, 546, 671-675
37.987Citations (PDF)
143PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data
Bioinformatics, 2017, 33, 2238-2240
4.763Citations (PDF)
144Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Cancer Discovery, 2017, 7, 596-609
25.1602Citations (PDF)
145Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Cell, 2017, 171, 540-556.e25
33.62,249Citations (PDF)
146The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK
Science Signaling, 2017, 10,
5.475Citations (PDF)
147Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Cancer Cell, 2017, 32, 155-168.e6
33.0128Citations (PDF)
148Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
Clinical Cancer Research, 2017, 23, 6094-6100
6.8197Citations (PDF)
149Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas
Cell, 2017, 171, 950-965.e28
33.6996Citations (PDF)
150Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
European Urology, 2017, 72, 952-959
2.1349Citations (PDF)
151OncoKB: A Precision Oncology Knowledge Base
JCO Precision Oncology, 2017, , 1-16
1.91,958Citations (PDF)
152A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers
PLoS Computational Biology, 2016, 12, e1004765
3.136Citations (PDF)
153GENT-31. PEDcBIOPORTAL: A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES
Neuro-Oncology, 2016, 18, vi80-vi80
1.04Citations (PDF)
154Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
New England Journal of Medicine, 2016, 375, 443-453
34.51,561Citations (PDF)
155The metabolic co-regulator PGC1α suppresses prostate cancer metastasis
Nature Cell Biology, 2016, 18, 645-656
16.3211Citations (PDF)
156Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease
Gastroenterology, 2016, 151, 278-287.e6
0.9190Citations (PDF)
157Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
Clinical Cancer Research, 2016, 22, 4623-4633
6.8198Citations (PDF)
158Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Cancer Cell, 2016, 29, 723-736
33.0594Citations (PDF)
159Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
Nature Communications, 2016, 7,
13.7172Citations (PDF)
160MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer
Nucleic Acids Research, 2016, 44, D986-D991
15.526Citations (PDF)
161rcellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R
Bioinformatics, 2016, 32, 1272-1274
4.744Citations (PDF)
162Deletions linked to TP53 loss drive cancer through p53-independent mechanisms
Nature, 2016, 531, 471-475
37.9245Citations (PDF)
163Translational Bioinformatics and Clinical Research (Biomedical) Informatics
Clinics in Laboratory Medicine, 2016, 36, 153-181
1.18Citations (PDF)
164Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Nature Medicine, 2016, 22, 369-378
33.0697Citations (PDF)
165Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications
Modern Pathology, 2016, 30, 599-609
4.8101Citations (PDF)
166Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism
JCI Insight, 2016, 1,
5.445Citations (PDF)
167Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Journal of Clinical Investigation, 2016, 126, 1052-1066
10.61,165Citations (PDF)
168Prognostic Significance of Genomic Alterations in Mantle Cell Lymphoma
Blood, 2016, 128, 4115-4115
4.80Citations (PDF)
169Integrative Clinical Genomics of Advanced Prostate Cancer
Cell, 2015, 161, 1215-1228
33.63,277Citations (PDF)
170Identification of low abundance microbiome in clinical samples using whole genome sequencing
Genome Biology, 2015, 16,
8.199Citations (PDF)
171Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder
European Urology, 2015, 67, 198-201
2.1135Citations (PDF)
172Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Cancer Discovery, 2015, 5, 842-849
25.1560Citations (PDF)
173Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
New England Journal of Medicine, 2015, 372, 2481-2498
34.53,041Citations (PDF)
174Translational Bioinformatics and Clinical Research (Biomedical) Informatics
Surgical Pathology Clinics, 2015, 8, 269-288
1.45Citations (PDF)
175Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations
Genome Biology, 2015, 16,
12.2163Citations (PDF)
176Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling
Molecular Cancer Therapeutics, 2015, 14, 278-288
1.931Citations (PDF)
177Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome
Neoplasia, 2015, 17, 183-189
7.038Citations (PDF)
178SomaticPOLEmutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
Neuro-Oncology, 2015, 17, 1356-1364
1.0109Citations (PDF)
179Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma
Neuro-Oncology, 2015, 17, 1344-1355
1.041Citations (PDF)
180The Molecular Taxonomy of Primary Prostate Cancer
Cell, 2015, 163, 1011-1025
33.62,929Citations (PDF)
181Pan-Cancer Analysis of Mutation Hotspots in Protein Domains
Cell Systems, 2015, 1, 197-209
5.8119Citations (PDF)
182Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Cell, 2015, 163, 506-519
33.61,817Citations (PDF)
183Genomic Characterization of Upper Tract Urothelial Carcinoma
European Urology, 2015, 68, 970-977
2.1261Citations (PDF)
184Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
Nature Biotechnology, 2015, 34, 155-163
29.8794Citations (PDF)
185Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
PLoS ONE, 2015, 10, e0126633
2.347Citations (PDF)
186Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles
Bioinformatics, 2014, 30, 2051-2059
4.732Citations (PDF)
187Copy number alteration burden predicts prostate cancer relapse
Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11139-11144
7.5342Citations (PDF)
188The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
Annals of Oncology, 2014, 25, 2372-2378
9.934Citations (PDF)
189Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Cell, 2014, 159, 676-690
33.62,848Citations (PDF)
190Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
Nature Genetics, 2014, 46, 424-426
25.2359Citations (PDF)
191Synthetic Lethality in ATM-Deficient RAD50 -Mutant Tumors Underlies Outlier Response to Cancer Therapy
Cancer Discovery, 2014, 4, 1014-1021
25.1121Citations (PDF)
192Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Cancer Research, 2014, 74, 2340-2350
3.8301Citations (PDF)
193Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Clinical Cancer Research, 2014, 20, 1955-1964
6.8220Citations (PDF)
194MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Cancer Cell, 2014, 25, 652-665
33.0312Citations (PDF)
195The landscape of somatic hypermutation in gynecologic cancer
Gynecologic Oncology, 2014, 135, 386-387
3.00Citations (PDF)
196Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication
Genome Research, 2014, 24, 1740-1750
4.6283Citations (PDF)
197Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis
Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8149-8154
7.590Citations (PDF)
198Genome-wide analysis of noncoding regulatory mutations in cancer
Nature Genetics, 2014, 46, 1160-1165
25.2507Citations (PDF)
199Collection, integration and analysis of cancer genomic profiles: from data to insight
Current Opinion in Genetics and Development, 2014, 24, 92-98
3.224Citations (PDF)
200Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival
European Urology, 2014, 65, 1191-1197
2.172Citations (PDF)
201BridgeDb app: unifying identifier mapping services for Cytoscape
F1000Research, 2014, 3, 148
0.511Citations (PDF)
202Evaluating cell lines as tumour models by comparison of genomic profiles
Nature Communications, 2013, 4,
13.71,335Citations (PDF)
203Analysis of microRNA-target interactions across diverse cancer types
Nature Structural and Molecular Biology, 2013, 20, 1325-1332
8.8196Citations (PDF)
204The Somatic Genomic Landscape of Glioblastoma
Cell, 2013, 155, 462-477
33.64,805Citations (PDF)
205The molecular diversity of Luminal A breast tumors
Breast Cancer Research and Treatment, 2013, 141, 409-420
2.3142Citations (PDF)
206Emerging landscape of oncogenic signatures across human cancers
Nature Genetics, 2013, 45, 1127-1133
25.21,324Citations (PDF)
207Pattern discovery and cancer gene identification in integrated cancer genomic data
Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4245-4250
7.5441Citations (PDF)
208MLH1‐silenced and non‐silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes
Journal of Pathology, 2013, 229, 99-110
4.969Citations (PDF)
209SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer
Cancer Cell, 2013, 24, 738-750
33.0160Citations (PDF)
210Using MEMo to Discover Mutual Exclusivity Modules in Cancer
Current Protocols in Bioinformatics, 2013, 41,
3.330Citations (PDF)
211Integrated genomic characterization of endometrial carcinoma
Nature, 2013, 497, 67-73
37.95,354Citations (PDF)
212The mutational landscape of adenoid cystic carcinoma
Nature Genetics, 2013, 45, 791-798
25.2450Citations (PDF)
213An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma
Journal of the National Cancer Institute, 2013, 105, 1862-1870
4.6272Citations (PDF)
214Cancer cells preferentially lose small chromosomes
International Journal of Cancer, 2013, 132, 2316-2326
4.3168Citations (PDF)
215Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network
Clinical Cancer Research, 2013, 19, 3259-3267
6.8350Citations (PDF)
216BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas
American Journal of Surgical Pathology, 2013, 37, 138-146
3.555Citations (PDF)
217Comprehensive Analysis of Long Non-Coding RNAs in Ovarian Cancer Reveals Global Patterns and Targeted DNA Amplification
PLoS ONE, 2013, 8, e80306
2.398Citations (PDF)
218Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
Cancer Research, 2012, 72, 6142-6152
3.8190Citations (PDF)
219Genomic Complexity and AKT Dependence in Serous Ovarian Cancer
Cancer Discovery, 2012, 2, 56-67
25.1116Citations (PDF)
220A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions
Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8212-8217
7.5163Citations (PDF)
221Mutual exclusivity analysis identifies oncogenic network modules
Genome Research, 2012, 22, 398-406
4.6651Citations (PDF)
22253BP1 Is a Haploinsufficient Tumor Suppressor and Protects Cells from Radiation Response in Glioma
Cancer Research, 2012, 72, 5250-5260
3.838Citations (PDF)
223MEF Promotes Stemness in the Pathogenesis of Gliomas
Cell Stem Cell, 2012, 11, 836-844
16.443Citations (PDF)
224Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma
PLoS ONE, 2012, 7, e34546
2.3114Citations (PDF)
225Integrative Subtype Discovery in Glioblastoma Using iCluster
PLoS ONE, 2012, 7, e35236
2.3230Citations (PDF)
226Time to Recurrence and Survival in Serous Ovarian Tumors Predicted from Integrated Genomic Profiles
PLoS ONE, 2011, 6, e24709
2.395Citations (PDF)
227Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression
Cancer Cell, 2011, 20, 173-186
33.0170Citations (PDF)
228Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas
Cancer Discovery, 2011, 1, 587-597
25.1121Citations (PDF)
229Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2
Silence: A Journal of RNA Regulation, 2011, 2, 3
1.785Citations (PDF)
23018F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
Cancer Research, 2011, 71, 5164-5174
3.8119Citations (PDF)
231Pathway Commons, a web resource for biological pathway data
Nucleic Acids Research, 2011, 39, D685-D690
15.51,049Citations (PDF)
232Integrative Genomic Profiling of Human Prostate Cancer
Cancer Cell, 2010, 18, 11-22
33.03,499Citations (PDF)
233Automated Network Analysis Identifies Core Pathways in Glioblastoma
PLoS ONE, 2010, 5, e8918
2.3327Citations (PDF)
234The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440
7.5272Citations (PDF)
235Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies
Nature Genetics, 2009, 42, 77-82
25.2379Citations (PDF)
236Expression patterns of mitotic and meiotic cell cycle regulators in testicular cancer and development
International Journal of Cancer, 2005, 116, 207-217
4.325Citations (PDF)
237Defining the spermatogonial stem cell
Developmental Biology, 2004, 269, 393-410
1.9130Citations (PDF)
238A multitude of genes expressed solely in meiotic or postmeiotic spermatogenic cells offers a myriad of contraceptive targets
Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12201-12206
7.5538Citations (PDF)
239Mitochondrial respiratory gene expression is suppressed in many cancers
ELife, 0, 6,
0.7126Citations (PDF)
240Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death
ELife, 0, 7,
0.7270Citations (PDF)
241Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma
ELife, 0, 8,
0.738Citations (PDF)